Keyword: Turing Pharmaceuticals
Share prices for leading generics companies took a big hit Thursday on news that the Department of Justice could file collusion charges by year’s end, a probe first unveiled by Bloomberg.
High-powered industry group PhRMA is raising hundreds of millions to fund a counteroffensive against drug-pricing action in the wake of next month's election.
Industry watchers wondering which biopharma company will land in hot water next for big price hikes may have their answer. Sen. Bernie Sanders and Rep. Elijah Cummings, who often have a hand in pharma affairs, have homed in on “staggering” price increases by Ariad Pharmaceuticals for leukemia drug Iclusig.
Ever since Mylan blamed PBMs in its EpiPen pricing defense, drugmakers and insurers have been fighting for the high ground on price hikes. Now, a leading PBM chief is the latest to push back against the idea that companies like his are responsible.
The specialty pharmacy space has been in somewhat of a rut when it comes to M&A--but that won’t last, Moody’s says.
While many pharma watchers are closely focused on the headlining presidential race this election season, a vote coming in California poses a big risk to the industry.
Yet another politician has seen enough big price hikes. Following a similar recommendation from Democratic nominee Hillary Clinton, a Connecticut congressional rep backed a pricing panel to crack down on the industry’s “bad actors.”
Payers and patients aren’t the only ones deeply concerned about U.S. drug price hikes. Hospitals have also been hit badly by hikes, a new report says, detailing some of the worst sticker shocks--and the high costs associated with them.
With drug prices dominating attention in Congress and agitating the public, GPhA CEO Chip Davis wants to be sure that low-cost generics are top of mind as a way to save money--and he has some ideas to amp up their strength in the marketplace.
Pharma execs now have more reason to worry about their pricing power. Democratic presidential candidate Hillary Clinton unveiled a slew of new proposals Friday, aiming to control price hikes on older meds.